JNJ-69086420 | m-entrepreneurship.com

Product Name :
JNJ-69086420

Search keywords :
JNJ-69086420

drugId :
null

Target Vo:
Kallikrein 2

Target Vo Short Name :
KLK2

Moa_Name:
Ionising radiation emitters

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Janssen Research & Development Llc

Active Company_Name :
Janssen Research & Development Llc

Active Indication_Name:
Prostatic Neoplasms

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Phase 1 Clinical

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
CD9 Antibody
Caspase 11 Antibody
Nrf2 Antibody(YA895): Nrf2 Antibody(YA895) is an unconjugated, approximately 68 kDa, rabbit-derived, anti-Nrf2(YA895) monoclonal antibody. Nrf2 Antibody(YA895) can be used for: WB, IHC-P, ICC/IF, IP, ChIP expriments in human, mouse background without labeling.

Author: Betaine hydrochloride

Related Posts